0T20 Stock Overview A clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Traws Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Traws Pharma Historical stock prices Current Share Price US$6.60 52 Week High US$29.75 52 Week Low US$6.60 Beta 1.36 1 Month Change 0% 3 Month Change -0.75% 1 Year Change -60.60% 3 Year Change -89.44% 5 Year Change -92.28% Change since IPO -99.58%
Recent News & Updates Traws Pharma, Inc. announced that it expects to receive $72.6 million in funding
Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu Dec 24
Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1) Nov 23
Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024 Oct 14
Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil Oct 08
Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor Oct 01 See more updates Traws Pharma, Inc. announced that it expects to receive $72.6 million in funding
Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu Dec 24
Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1) Nov 23
Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024 Oct 14
Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil Oct 08
Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor Oct 01 Nasdaq Determines to Delist Traws Pharma's Securities Sep 28
Traws Pharma, Inc. Announces Board Changes Sep 21
Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Aug 25 Traws Pharma, Inc. announced delayed 10-Q filing Aug 16
Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024 Aug 15
New minor risk - Shareholder dilution Jun 06
First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2023) May 17
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy May 08
High number of new directors Apr 08
Traws Pharma, Inc. Announces Chief Executive Office Changes Apr 05 Traws Pharma, Inc. Announces Board Changes
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc Apr 02
Full year 2023 earnings released: US$0.90 loss per share (vs US$0.91 loss in FY 2022) Apr 02
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma Dec 13
New major risk - Share price stability Dec 12
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s Dec 09
Third quarter 2023 earnings released: US$0.23 loss per share (vs US$0.26 loss in 3Q 2022) Nov 17
Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer Oct 25
Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement Oct 01
Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.19 loss in 2Q 2022) Aug 13
Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma Jun 15
Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023 Jun 09
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade May 26
First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.20 loss in 1Q 2022) May 16
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer May 12
Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023 May 05
Full year 2022 earnings released: US$0.91 loss per share (vs US$0.96 loss in FY 2021) Mar 18
Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma Feb 08
Insufficient new directors Dec 26
Onconova Therapeutics, Inc. Announces Board Appointments Dec 20
Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.22 loss in 3Q 2021) Nov 16
Onconova Therapeutics, Inc. Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer Nov 15
Onconova Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 08
Onconova Therapeutics, Inc. Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022 Sep 13
Second quarter 2022 earnings released: EPS: US$0 (vs US$0.27 loss in 2Q 2021) Aug 13
Onconova Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Onconova Therapeutics, Inc., Annual General Meeting, Aug 18, 2022 Jul 22
Onconova Therapeutics, Inc. Announces Executive Changes Jun 14 Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2022
First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021) May 13
Onconova Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022 May 05
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 19
Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma Dec 03
Onconova Therapeutics, Inc. Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer Sep 24
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement Jun 23
Onconova Therapeutics, Inc. Announces the Publication of a Preclinical Study in the Journal Molecular Cancer Jun 18
Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300 May 22
Onconova Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 11, 2021 Mar 05
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement Feb 25
Onconova Therapeutics, Inc. Announces Resignation of Richard C. Woodman, MD, Senior Vice President Chief Medical Officer Jan 16
Onconova Therapeutics, Inc. Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300 Dec 23
Manoj Maniar, Ph.D., Senior Vice President, Product Development departs from Onconova Therapeutics, Inc Dec 20
Onconova Therapeutics Files Investigational New Drug Application for Multi-Kinase CDK4/6 Inhibitor ON 123300 Nov 25
Onconova Therapeutics, Inc. to Report Q3, 2020 Results on Nov 12, 2020 Nov 06
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals Sep 22
Onconova Therapeutics, Inc. to Report Q2, 2020 Results on Aug 12, 2020 Aug 08
Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement Aug 06 Shareholder Returns 0T20 DE Pharmaceuticals DE Market 7D 0% -0.2% -0.4% 1Y -60.6% -17.1% 7.9%
See full shareholder returns
Return vs Market: 0T20 underperformed the German Market which returned 7.1% over the past year.
Price Volatility Is 0T20's price volatile compared to industry and market? 0T20 volatility 0T20 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.1% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0T20's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 0T20's volatility change over the past year.
About the Company Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers.
Show more Traws Pharma, Inc. Fundamentals Summary How do Traws Pharma's earnings and revenue compare to its market cap? 0T20 fundamental statistics Market cap €14.62m Earnings (TTM ) -€134.13m Revenue (TTM ) €215.31k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0T20 income statement (TTM ) Revenue US$226.00k Cost of Revenue US$0 Gross Profit US$226.00k Other Expenses US$141.01m Earnings -US$140.78m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -46.53 Gross Margin 100.00% Net Profit Margin -62,294.25% Debt/Equity Ratio 0%
How did 0T20 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 04:03 End of Day Share Price 2024/09/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Traws Pharma, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Thomas Cooper Edison Investment Research Etzer Darout Guggenheim Securities, LLC Michael Schmidt Guggenheim Securities, LLC
Show 5 more analysts 
